Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 16.250-16.250 for the period, compared to the consensus earnings per share estimate of 16.410. The company issued revenue guidance of -.

Humana Stock Down 1.9 %

NYSE:HUM traded down $4.84 during trading hours on Monday, reaching $248.93. 585,778 shares of the stock were exchanged, compared to its average volume of 1,566,528. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a 50 day moving average of $267.58 and a 200 day moving average of $271.55. The stock has a market cap of $30.04 billion, a PE ratio of 25.01, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts expect that Humana will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.42%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio is 35.58%.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. StockNews.com downgraded Humana from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Humana presently has an average rating of "Hold" and a consensus target price of $280.17.

Hedge Funds Weigh In On Humana

An institutional investor recently bought a new position in Humana stock. Revolve Wealth Partners LLC purchased a new stake in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 798 shares of the insurance provider's stock, valued at approximately $202,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.